These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19342098)

  • 1. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor.
    Imai N; Miwa H; Shikami M; Suganuma K; Gotoh M; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Shitara K; Shibuya M; Nitta M
    Leuk Res; 2009 Dec; 33(12):1650-7. PubMed ID: 19342098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
    Imai N; Shikami M; Miwa H; Suganuma K; Hiramatsu A; Watarai M; Satoh A; Itoh M; Imamura A; Mihara H; Nitta M
    Br J Haematol; 2006 Dec; 135(5):673-82. PubMed ID: 17107349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
    List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
    Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
    Reichert F; Barak V; Tarshis M; Prindull G; Tarshis E; Ben-Ishay Z
    Eur J Haematol; 2005 Jul; 75(1):41-6. PubMed ID: 15946309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis.
    Banerjee S; Mehta S; Haque I; Sengupta K; Dhar K; Kambhampati S; Van Veldhuizen PJ; Banerjee SK
    Biochemistry; 2008 Mar; 47(11):3345-51. PubMed ID: 18284215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E.
    Shibuya M
    Endothelium; 2006; 13(2):63-9. PubMed ID: 16728325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.
    Shin JY; Yoon IH; Kim JS; Kim B; Park CG
    Cell Immunol; 2009; 256(1-2):72-8. PubMed ID: 19249018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.
    Carrillo de Santa Pau E; Arias FC; Caso Peláez E; Muñoz Molina GM; Sánchez Hernández I; Muguruza Trueba I; Moreno Balsalobre R; Sacristán López S; Gómez Pinillos A; del Val Toledo Lobo M
    Cancer; 2009 Apr; 115(8):1701-12. PubMed ID: 19197998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML.
    Hiramatsu A; Miwa H; Shikami M; Ikai T; Tajima E; Yamamoto H; Imai N; Hattori A; Kyo T; Watarai M; Miura K; Satoh A; Itoh M; Imamura A; Mihara H; Katoh Y; Nitta M
    Leuk Lymphoma; 2006 Jan; 47(1):89-95. PubMed ID: 16465716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
    Balaian L; Ball ED
    Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
    Weidenaar AC; de Jonge HJ; Fidler V; ter Elst A; Meeuwsen-de Boer T; Douwes J; Bouma-ter Steege JC; Hählen K; Kamps WA; de Bont ES
    Anticancer Drugs; 2008 Jan; 19(1):45-54. PubMed ID: 18043129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional VEGF and VEGF receptors are expressed in human medulloblastomas.
    Slongo ML; Molena B; Brunati AM; Frasson M; Gardiman M; Carli M; Perilongo G; Rosolen A; Onisto M
    Neuro Oncol; 2007 Oct; 9(4):384-92. PubMed ID: 17704359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects.
    Detoraki A; Staiano RI; Granata F; Giannattasio G; Prevete N; de Paulis A; Ribatti D; Genovese A; Triggiani M; Marone G
    J Allergy Clin Immunol; 2009 May; 123(5):1142-9, 1149.e1-5. PubMed ID: 19275959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation.
    Saulle E; Riccioni R; Coppola S; Parolini I; Diverio D; Riti V; Mariani G; Laufer S; Sargiacomo M; Testa U
    Br J Haematol; 2009 May; 145(3):399-411. PubMed ID: 19245429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.
    Weidenaar AC; Ter Elst A; Kampen KR; Meeuwsen-de Boer T; Kamps WA; Schuringa JJ; de Bont ES
    Mol Cancer Res; 2013 Apr; 11(4):339-48. PubMed ID: 23393162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.
    Park JH; Kim SH; Choi MC; Lee J; Oh DY; Im SA; Bang YJ; Kim TY
    Biochem Biophys Res Commun; 2008 Apr; 368(2):318-22. PubMed ID: 18211808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blocking enhancive effect of vascular endothelial growth factor on proliferation of rhabdomyosarcoma cell line RH4 by avastin].
    Li ZG; Shi YX; Peng RJ; Zhu MQ; Wan YY
    Ai Zheng; 2006 Jun; 25(6):718-22. PubMed ID: 16764767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.